| Infiltrating lobular carcinoma of the breast: tumor characteristics and clinical outcome G Arpino, VJ Bardou, GM Clark, RM Elledge Breast cancer research 6, 1-8, 2004 | 1095 | 2004 |
| Progesterone receptor status significantly improves outcome prediction over estrogen receptor status alone for adjuvant endocrine therapy in two large breast cancer databases VJ Bardou, G Arpino, RM Elledge, CK Osborne, GM Clark Journal of clinical oncology 21 (10), 1973-1979, 2003 | 1037 | 2003 |
| Phase III randomized study of ribociclib and fulvestrant in hormone receptor–positive, human epidermal growth factor receptor 2–negative advanced breast cancer: MONALEESA-3 DJ Slamon, P Neven, S Chia, PA Fasching, M De Laurentiis, SA Im, ... Journal of Clinical Oncology 36 (24), 2465-2472, 2018 | 943 | 2018 |
| Crosstalk between the estrogen receptor and the HER tyrosine kinase receptor family: molecular mechanism and clinical implications for endocrine therapy resistance G Arpino, L Wiechmann, CK Osborne, R Schiff Endocrine reviews 29 (2), 217-233, 2008 | 652 | 2008 |
| Biology of progesterone receptor loss in breast cancer and its implications for endocrine therapy X Cui, R Schiff, G Arpino, CK Osborne, AV Lee Journal of clinical oncology 23 (30), 7721-7735, 2005 | 636 | 2005 |
| Estrogen receptor–positive, progesterone receptor–negative breast cancer: association with growth factor receptor expression and tamoxifen resistance G Arpino, H Weiss, AV Lee, R Schiff, S De Placido, CK Osborne, ... Journal of the National Cancer Institute 97 (17), 1254-1261, 2005 | 634 | 2005 |
| A meta-analysis on the interaction between HER-2 expression and response to endocrine treatment in advanced breast cancer M De Laurentiis, G Arpino, E Massarelli, A Ruggiero, C Carlomagno, ... Clinical cancer research 11 (13), 4741-4748, 2005 | 425 | 2005 |
| HER-2 amplification, HER-1 expression, and tamoxifen response in estrogen receptor-positive metastatic breast cancer: a southwest oncology group study G Arpino, SJ Green, DC Allred, D Lew, S Martino, CK Osborne, ... Clinical cancer research 10 (17), 5670-5676, 2004 | 310 | 2004 |
| Adenoid cystic carcinoma of the breast: molecular markers, treatment, and clinical outcome G Arpino, GM Clark, S Mohsin, VJ Bardou, RM Elledge Cancer 94 (8), 2119-2127, 2002 | 262 | 2002 |
| Treatment of triple negative breast cancer (TNBC): current options and future perspectives M De Laurentiis, D Cianniello, R Caputo, B Stanzione, G Arpino, S Cinieri, ... Cancer treatment reviews 36, S80-S86, 2010 | 248 | 2010 |
| Premalignant and in situ breast disease: biology and clinical implications G Arpino, R Laucirica, RM Elledge Annals of internal medicine 143 (6), 446-457, 2005 | 244 | 2005 |
| Androgen receptor in triple negative breast cancer: A potential target for the targetless subtype L Gerratana, D Basile, G Buono, S De Placido, M Giuliano, S Minichillo, ... Cancer treatment reviews 68, 102-110, 2018 | 239 | 2018 |
| Clinical and biologic features of triple-negative breast cancers in a large cohort of patients with long-term follow-up L Malorni, PB Shetty, C De Angelis, S Hilsenbeck, MF Rimawi, R Elledge, ... Breast cancer research and treatment 136, 795-804, 2012 | 235 | 2012 |
| Treatment of human epidermal growth factor receptor 2–overexpressing breast cancer xenografts with multiagent HER-targeted therapy G Arpino, C Gutierrez, H Weiss, M Rimawi, S Massarweh, L Bharwani, ... Journal of the National Cancer Institute 99 (9), 694-705, 2007 | 226 | 2007 |
| Perspective on circulating tumor cell clusters: why it takes a village to metastasize M Giuliano, A Shaikh, HC Lo, G Arpino, S De Placido, XH Zhang, ... Cancer research 78 (4), 845-852, 2018 | 208 | 2018 |
| First-line trastuzumab plus an aromatase inhibitor, with or without pertuzumab, in human epidermal growth factor receptor 2–positive and hormone receptor–positive metastatic or … M Rimawi, JM Ferrero, J de la Haba-Rodriguez, C Poole, S De Placido, ... Journal of Clinical Oncology 36 (28), 2826-2835, 2018 | 201 | 2018 |
| Advanced concepts in estrogen receptor biology and breast cancer endocrine resistance: implicated role of growth factor signaling and estrogen receptor coregulators R Schiff, SA Massarweh, J Shou, L Bharwani, G Arpino, M Rimawi, ... Cancer chemotherapy and pharmacology 56, 10-20, 2005 | 191 | 2005 |
| CDK 4/6 inhibitors as single agent in advanced solid tumors F Schettini, I De Santo, CG Rea, P De Placido, L Formisano, M Giuliano, ... Frontiers in oncology 8, 608, 2018 | 187 | 2018 |
| Endocrine treatment versus chemotherapy in postmenopausal women with hormone receptor-positive, HER2-negative, metastatic breast cancer: a systematic review and network meta … M Giuliano, F Schettini, C Rognoni, M Milani, G Jerusalem, T Bachelot, ... The Lancet Oncology 20 (10), 1360-1369, 2019 | 174 | 2019 |
| Human epidermal growth factor receptor 2 (HER2)-positive and hormone receptor-positive breast cancer: new insights into molecular interactions and clinical implications F Montemurro, S Di Cosimo, G Arpino Annals of Oncology 24 (11), 2715-2724, 2013 | 167 | 2013 |
